1. Japanese experience of screening
- Author
-
Junji Hanai, Nobuo Takasugi, Motoi Nishi, Yasumasa Sato, Takeo Takeda, Yoshio Hatae, and Nakadate H
- Subjects
Male ,Paper ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Vanillyl Mandelic Acid ,Urine ,Neuroblastoma ,Vanilmandelic Acid ,Japan ,medicine ,Humans ,Mass Screening ,Urinary concentration ,Duodenal Perforation ,Chromatography, High Pressure Liquid ,business.industry ,Incidence (epidemiology) ,Infant ,Homovanillic Acid ,medicine.disease ,Survival Analysis ,Quantitative determination ,Oncology ,Screening for Neuroblastoma ,Pediatrics, Perinatology and Child Health ,Female ,Reagent Kits, Diagnostic ,business - Abstract
In Sapporo City, the mass-screening for neuroblastoma concerning the urine of infants at about 6 months of age, started in 1981. After 1984, the quantitative determination of VMA, HVA in the urine was carried out using high performance liquid chromatography from the first step. About 104,000 babies have received the screening during the last 7 years, and 19 patients were found (incidence of detection 1:5,500). Except for one, who died of the duodenal perforation shortly after the surgery, all other patients are surviving free from disease. Among 10,000 neonates, we determined urinary concentration of VMA, HVA, and no positive cases were found. However, from this group, 2 patients we detected by the mass-screening at 6 months of age (1:5,000). After the start of mass-screening, the number of the patients with this tumor in much earlier stages and younger ages increased, clarifying that the main cause for improvement of the survival rates of neuroblastoma in Sapporo.
- Published
- 1989